The presence or absence of certain molecular markers, namely, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2), is used to classify BC as follows: hormone receptor (HR) positive/HER2 negative (HR+/HER2-) BC, occurring in around 70% of patients; HER2 positive (HR+/−/HER2+) BC, accounting for 15–20% of patients; and triple-negative (HR−/HER2−) BC (TNBC), occurring in 15% of patients, a frequently recurring BC, and the most aggressive and lethal BC subtype in women. The gene discussed is PGR; the disease is breast cancer.